{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:12:12Z","timestamp":1790892732093,"version":"4.1.0"},"reference-count":97,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["NANOTEC"],"published-print":{"date-parts":[[2020,9,16]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Psoriasis is a chronic autoimmune disorder of the skin which is characterized by the reoccurring episodes of inflammatory lesions with a worldwide occurrence of around 2-5%. Psoriasis can be categorized as mild, moderate and severe conditions. In mild psoriasis, there is the formation of rashes, and when it becomes moderate, the skin turns scaly. In severe conditions, the red patches can be seen on the skin surface and the skin becomes itchy. The different treatment approaches include phototherapy, topical, oral and other systemic drug deliveries. Dermal treatment is now highly endorsed in topical indications for psoriatic patients, due to its higher penetration which can be achieved using pharmaceutical carriers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>Though various conventional formulations are there, therapeutic benefits can be provided only to a limited extent. The objective of this review was to highlight newer biocompatible and biodegradable materials like phospholipids, and forefront drug delivery methods like liposomes, microemulsions, nanoemulsions, niosomes, ethosomes, etc. which has increased the possibility to improve the efficacy and safety of the topical products. Apart from this, many medicinal plants are available in nature that are used for treating skin diseases like psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>The new trends in nanotechnology are marked by subsequent changes in the pharmaceutical research field. To safeguard the research works in the research field, various patents have been introduced, such as Glaxo Smith Kline (GSK 2981278) \u2013 ROR\u03b3 antagonist, etc. The causes, pathophysiology and the herbal plants that are used in treating the disease are also discussed.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1872210514666200204124130","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T12:34:00Z","timestamp":1580819640000},"page":"102-118","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["An Overview on Promising Nanotechnological Approaches for the Treatment of Psoriasis"],"prefix":"10.2174","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5810-0501","authenticated-orcid":true,"given":"Kalpana","family":"Pandey","sequence":"first","affiliation":[{"name":"Amity Institute of Pharmacy, Amity University Uttar Pradesh, Lucknow Campus, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6566-6335","authenticated-orcid":true,"family":"Nimisha","sequence":"additional","affiliation":[{"name":"Amity Institute of Pharmacy, Amity University Uttar Pradesh, Lucknow Campus, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"1529","volume":"19(3)","author":"Wang,Z.","year":"2019","unstructured":"Wang Z, Zheng H, Zhou H.;et al. Systematic screening and identi-fication of novel psoriasis-specific genes from the transcriptome of psoriasis-like keratinocytes. Mol Med Rep. 2019; 19(3): 1529-42. PMID: 30592269","journal-title":"Mol Med Rep"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jddst.2018.12.020","volume":"49","author":"Rajitha,P.","year":"2019","unstructured":"Rajitha,P.; Shammika,P.; Aishwar,ya,S.; Gopikrishnan,A.; Jayakumar,R.; Sabitha,M. Chaulmoogra oil based methotrexate loaded topical nanoemulsion for the treatment of psoriasis. J Drug Deliv Sci Te-chnol. 2019; 49: 463-76. http:\/\/dx.doi.org\/10.1016\/j.jddst.2018.12.020","journal-title":"J Drug Deliv Sci Te-chnol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.4103\/0378-6323.72451","volume":"76(6)","author":"Katare,OP.","year":"2010","unstructured":"Katare,OP.; Raza,K.; Singh,B.; Dogra,S. Novel drug delivery sys-tems in topical treatment of psori asis: Rigors and vigors. Indian J Dermatol Venereol Leprol. 2010; 76(6): 612-21. http:\/\/dx.doi.org\/10.4103\/0378-6323.72451 PMID: 21079304","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref=4","unstructured":"Women\u2019s health illness and disabilities-psoriasis; natural lifestyle advisor). 2010 (Accessed 5 April 2016)"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.clindermatol.2019.01.011","volume":"37(2)","author":"Lewis,DJ.","year":"2019","unstructured":"Lewis,DJ.; Chan,WH.; Hinojosa,T.; Hsu,S.; Feldman,SR. Mecha-nisms of microbial pathogenesis and the role of the skin microbio-me in psoriasis: A review. Clin Dermatol. 2019; 37(2): 160-6. http:\/\/dx.doi.org\/10.1016\/j.clindermatol.2019.01.011 PMID: 30981296","journal-title":"Clin Dermatol"},{"key":"ref=6","author":"Daniel,J.","unstructured":"Daniel,J.; Roach,P.; Hartmann,J. 978-3-12 (Accessed 5 April 2016). ."},{"key":"ref=7","author":"Kuchekar,AB.","unstructured":"Kuchekar,AB.; Pujari,RR.; Kuchekar,SB.; Dhole,SN.; Mule,PM. Psoriasis: A comprehensive review. Int J Pharm Life Sci. 2011; 2(6)","journal-title":"Int J Pharm Life Sci"},{"key":"ref=8","first-page":"264","volume":"1(3)","author":"Victor,FC.","year":"2002","unstructured":"Victor,FC.; Gottlieb,AB. TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol. 2002; 1(3): 264-75. PMID: 12851985","journal-title":"J Drugs Dermatol"},{"key":"ref=9","author":"Rahman,P. .","unstructured":"Rahman,P.; Elder,JT. Genetic epidemiology of psoriasis and psoria-tic arthritis. Ann Rheum Dis. 2005; 64(Suppl","journal-title":"Ann Rheum Dis"},{"key":"ref=10","first-page":"406","volume":"13(4)","author":"Kawamura,A.","year":"2003","unstructured":"Kawamura,A.; Ochiai,T. Candesartan cilexetil induced pustular psoriasis. Eur J Dermatol. 2003; 13(4): 406-7. PMID: 12948927","journal-title":"Eur J Dermatol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/000155501317140007","volume":"81(5)","author":"Steckelings,UM.","year":"2001","unstructured":"Steckelings,UM.; Artuc,M.; Wollschl\u00e4ger,T.; Wiehstutz,S.; Henz,BM. Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions. Acta Derm Venereol. 2001; 81(5): 321-5. http:\/\/dx.doi.org\/10.1080\/000155501317140007 PMID: 11800136","journal-title":"Acta Derm Venereol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.7748\/phc.26.3.32.s33","volume":"26(3)","author":"Shan Y","year":"2016","unstructured":"Shan Y. Treatment and management of psoriasis. Prim Health Care. 2016; 26(3): 32-41","journal-title":"Prim Health Care"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"5451.","DOI":"10.4081\/dr.2014.5451","volume":"6(1)","author":"Vincent,N.","year":"2014","unstructured":"Vincent,N.; Ramya,DD.; Vedha,HB. Progress in psoriasis therapy via novel drug delivery systems. Dermatol Rep. 2014; 6(1): 5451. http:\/\/dx.doi.org\/10.4081\/dr.2014.5451 PMID: 25386329","journal-title":"Dermatol Rep"},{"key":"ref=14","first-page":"8","volume":"1(1)","author":"Thaker,SJ.","year":"2010","unstructured":"Thaker,SJ.; Mehta,DS.; Shah,HA.; Dave,JN.; Mundhava,SG. A com-parative randomized open label study to evaluate. Indian Dermatol Online J. 2010; 1(1): 8-9","journal-title":"Indian Dermatol Online J"},{"key":"ref=15","author":"Krueger,JG. .","unstructured":"Krueger,JG.; Bowcock,A. Psoriasis pathophysiology: Current con-cepts of pathogenesis. Ann Rheum Dis. 2005; 64(Suppl","journal-title":"Ann Rheum Dis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10072-009-0184-x","volume":"31(3)","author":"La,Mantia,L","year":"2010","unstructured":"La Mantia,L.; Capsoni,F. Psoriasis during interferon beta treatment for multiple sclerosis. Neurol Sci. 2010; 31(3): 337-9. http:\/\/dx.doi.org\/10.1007\/s10072-009-0184-x PMID: 19924503","journal-title":"Neurol Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1185\/03007997609109283","volume":"4(1)","author":"Lassus,A","year":"1976","unstructured":"Lassus A. A comparative pilot study of azapropazone and indome-thacin in the treatment of psoriatic arthritis and Reiter\u2019s disease. Curr Med Res Opin. 1976; 4(1): 65-9. http:\/\/dx.doi.org\/10.1185\/03007997609109283 PMID: 770082","journal-title":"Curr Med Res Opin"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"138S","DOI":"10.1111\/1523-1747.ep12875040","volume":"95(6) (Suppl.)","author":"Fierlbeck,G.","year":"1990","unstructured":"Fierlbeck,G.; Rassner,G. Treatment of psoriasis and psoriatic arthri-tis with interferon gamma. J Invest Dermatol. 1990; 95(6) (Suppl.): 138S-41S. http:\/\/dx.doi.org\/10.1111\/1523-1747.ep12875040 PMID: 2124243","journal-title":"J Invest Dermatol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1001\/archderm.1994.01690020082014","volume":"130(2)","author":"Elder,JT.","year":"1994","unstructured":"Elder,JT.; Nair,RP.; Guo,SW.; Henseler,T.; Christophers,E.; Voorhees,JJ. The genetics of psoriasis. Arch Dermatol. 1994; 130(2): 216-24. http:\/\/dx.doi.org\/10.1001\/archderm.1994.01690020082014 PMID: 8304761","journal-title":"Arch Dermatol"},{"key":"ref=20","author":"Mahajan,R. .","unstructured":"Mahajan,R.; Handa,S. Pathophysiology of psoriasis. Indian J Der-matol Venereol Leprol. 2013; 79(7) (Suppl","journal-title":"Indian J Der-matol Venereol Leprol"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04412.x","author":"Langley,RG","unstructured":"Langley RG. Effective and sustainable biologic treatment of pso-riasis: What can we learn from new clinical data? J Eur Acad Der-matol Venereol. 2012; 26(Suppl. 2): 21-9. http:\/\/dx.doi.org\/10.1111\/j.1468-3083.2011.04412.x PMID: 22356632","journal-title":"2012; 26(Suppl"},{"key":"ref=22","author":"Raghuwanshi,N.","unstructured":"Raghuwanshi,N.; Yadav,TC.; Srivastava,AK.; Raj,U.; Varadwaj,P.; Pruthi,V. Structure-based drug designing and identification of Woodfordia fruticosa inhibitors targeted against heat shock protein (HSP70-1) as suppressor for Imiquimod-induced psoriasis like skin inflammation in mice model. Mater Sci Eng C 2019; 95: 57-71. http:\/\/dx.doi.org\/10.1016\/j.msec.2018.10.061 PMID: 30573271.","journal-title":"Mater Sci Eng C"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.4049\/jimmunol.151.11.6535","volume":"151(11)","author":"Nestle,FO.","year":"1993","unstructured":"Nestle,FO.; Zheng,XG.; Thompson,CB.; Turka,LA.; Nickoloff,BJ. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J Immunol. 1993; 151(11): 6535-45. PMID: 7504023","journal-title":"J Immunol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1242\/dmm.009092","volume":"5(4)","author":"Johnson-Huang,LM.","year":"2012","unstructured":"Johnson-Huang,LM.; Lowes,MA.; Krueger,JG. Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech. 2012; 5(4): 423-33. http:\/\/dx.doi.org\/10.1242\/dmm.009092 PMID: 22730473","journal-title":"Dis Model Mech"},{"key":"ref=25","first-page":"115","volume":"2(1)","author":"Gall,JS.","year":"2008","unstructured":"Gall,JS.; Kalb,RE. Infliximab for the treatment of plaque psoriasis. Biologics. 2008; 2(1): 115-24. PMID: 19707434","journal-title":"Biologics"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1365-2133.1987.tb07364.x","volume":"117(6)","author":"Powles,AV.","year":"1987","unstructured":"Powles,AV.; Griffiths,CE.; Seifert,MH.; Fry,L. Exacerbation of pso-riasis by indomethacin. Br J Dermatol. 1987; 117(6): 799-800. http:\/\/dx.doi.org\/10.1111\/j.1365-2133.1987.tb07364.x PMID: 3426958","journal-title":"Br J Dermatol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"31.e1","DOI":"10.1016\/j.jaad.2006.07.017","volume":"56(1)","author":"Menter,A.","year":"2007","unstructured":"Menter A, Feldman SR, Weinstein GD.;et al. A randomized com-parison of continuous vs. intermittent infliximab maintenance re-gimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007; 56(1): 31.e1-31.e15. http:\/\/dx.doi.org\/10.1016\/j.jaad.2006.07.017 PMID: 17097378","journal-title":".J Am Acad Dermatol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3109\/00048678709158929","volume":"21(4)","author":"Skerritt,PW","year":"1987","unstructured":"Skerritt PW. Psoriatic arthritis during lithium therapy. Aust N Z J Psychiatry. 1987; 21(4): 601-4. http:\/\/dx.doi.org\/10.3109\/00048678709158929 PMID: 3130043","journal-title":"Aust N Z J Psychiatry"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s13671-019-0248-y","volume":"8(1)","author":"Murphy,EC.","year":"2019","unstructured":"Murphy,EC.; Schaffter,SW.; Friedman,AJ. Nanotechnology for psoriasis therapy. Curr Dermatol Rep. 2019; 8(1): 14-25","journal-title":"Curr Dermatol Rep"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0190-9622(08) 80533-6","volume":"26(1)","author":"Rudolph,RI","year":"1992","unstructured":"Rudolph RI. Lithium-induced psoriasis of the fingernails. J Am Acad Dermatol. 1992; 26(1): 135-6. http:\/\/dx.doi.org\/10.1016\/S0190-9622(08) 80533-6 PMID: 1732326","journal-title":"J Am Acad Dermatol"},{"key":"ref=31","author":"Farahnik,B.","unstructured":"Farahnik B, Beroukhim K, Abrouk M.;et al. Brodalumab for the treatment of psoriasis"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s13555-016-0121-x","volume":"6(2)","author":"Farahnik,B.","year":"2016","unstructured":"Farahnik B, Beroukhim K, Abrouk M.;et al. A review of phase III trials. Dermatol Ther (Heidelb). 2016; 6(2): 111-24. http:\/\/dx.doi.org\/10.1007\/s13555-016-0121-x PMID: 27221323","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref=33","author":"Source: Drugs.com","unstructured":"Source: Drugs.com. Statistics. 2013; Q4www.druhs.com\/ stats\/top100\/2013\/q4\/sales (Accessed 5 April 2016)"},{"key":"ref=34","author":"Mrowietz,U.","unstructured":"Mrowietz,U.; Kragballe,K.; Nast,A.; Reich,K. Strategies for impro-ving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting. J Eur Acad Dermatol Ve-nereol. 2011; 25(Suppl","journal-title":"J Eur Acad Dermatol Ve-nereol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/bjd.15551","volume":"177(3)","author":"Davison,NJ.","year":"2017","unstructured":"Davison NJ, Warren RB, Mason KJ.;et al. Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study. Br J Dermatol. 2017; 177(3): 828-36. http:\/\/dx.doi.org\/10.1111\/bjd.15551 PMID: 28386916","journal-title":"Br J Dermatol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e67078.","DOI":"10.1371\/journal.pone.0067078","volume":"8(6)","author":"Sun,J.","year":"2013","unstructured":"Sun,J.; Zhao,Y.; Hu,J. Curcumin inhibits imiquimod-induced psoria-sis-like inflammation by inhibiting IL-1beta and IL-6 production in mice. PLoS One. 2013; 8(6): e67078. http:\/\/dx.doi.org\/10.1371\/journal.pone.0067078 PMID: 23825622","journal-title":"PLoS One"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S0738-081X(01) 00183-3","volume":"19(4)","author":"Morganti,P.","year":"2001","unstructured":"Morganti,P.; Ruocco,E.; Wolf,R.; Ruocco,V. Percutaneous ab-sorption and delivery systems. Clin Dermatol. 2001; 19(4): 489-501. http:\/\/dx.doi.org\/10.1016\/S0738-081X(01) 00183-3 PMID: 11535394","journal-title":"Clin Dermatol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1146\/annurev.immunol.15.1.749","volume":"15","author":"Boehm,U.","year":"1997","unstructured":"Boehm,U.; Klamp,T.; Groot,M.; Howard,JC. Cellular responses to interferon-gamma. Annu Rev Immunol. 1997; 15: 749-95. http:\/\/dx.doi.org\/10.1146\/annurev.immunol.15.1.749 PMID: 9143706","journal-title":"Annu Rev Immunol"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1517\/17425247.2015.982088","volume":"312(4)","author":"Rahman,M.","year":"2015","unstructured":"Rahman,M.; Akhter,S.; Ahmad,J. Nano medicine-based drug targe-ting for psoriasis: Potentials and emerging trends in nanoscale pharmacotherapy. Epert opinion on drug delivery. 2015; 312(4): 635-52","journal-title":"Epert opinion on drug delivery"},{"key":"ref=40","first-page":"71","volume":"11(4)","author":"Patel,R.","year":"2009","unstructured":"Patel,R.; Singh,SK.; Singh,S.; Sheth,NR.; Gendle,R. Development and characterization of curcumin loaded transfersome for trans-dermal delivery. Journal of pharmaceutical sciences and research. 2009; 11(4): 71","journal-title":"Journal of pharmaceutical sciences and research"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/1567201052772915","volume":"2(1)","author":"Benson,HA","year":"2005","unstructured":"Benson HA. Transdermal drug delivery: Penetration enhancement techniques. Curr Drug Deliv. 2005; 2(1): 23-33. http:\/\/dx.doi.org\/10.2174\/1567201052772915 PMID: 16305405","journal-title":"Curr Drug Deliv"},{"key":"ref=42","author":"2","unstructured":"2. Zhang H, Zhai Y, Wang J, Zhai G. New progress and prospects: The application of nanogel in drug delivery. Mater Sci Eng C 2016; 60: 560-8. http:\/\/dx.doi.org\/10.1016\/j.msec.2015.11.041","journal-title":".Mater Sci Eng C"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejps.2016.09.007","volume":"96","author":"Panonnummal,R.","year":"2017","unstructured":"Panonnummal,R.; Jayakumar,R.; Sabitha,M. Comparative anti-psoriatic efficacy studies of clobetasol loaded chitin nanogel and marketed cream. Eur J Pharm Sci. 2017; 96: 193-206. http:\/\/dx.doi.org\/10.1016\/j.ejps.2016.09.007 PMID: 27615594","journal-title":"Eur J Pharm Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ejpb.2016.06.019","volume":"107","author":"Divya,G.","year":"2016","unstructured":"Divya,G.; Panonnummal,R.; Gupta,S.; Jayakumar,R.; Sabitha,M. Acitretin and aloe-emodin loaded chitin nanogel for the treatment of psoriasis. Eur J Pharm Biopharm. 2016; 107: 97-109. http:\/\/dx.doi.org\/10.1016\/j.ejpb.2016.06.019 PMID: 27368748","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jconrel.2007.08.005","volume":"123(2)","author":"Dubey,V.","year":"2007","unstructured":"Dubey,V.; Mishra,D.; Dutta,T.; Nahar,M.; Saraf,DK.; Jain,NK. Der-mal and transdermal delivery of an anti-psoriatic agent via ethano-lic liposomes. J Control Release. 2007; 123(2): 148-54. http:\/\/dx.doi.org\/10.1016\/j.jconrel.2007.08.005 PMID: 17884226","journal-title":"J Control Release"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"16071.","DOI":"10.1038\/natrevmats.2016.71","volume":"1(12)","author":"Li,J.","year":"2016","unstructured":"Li,J.; Mooney,DJ. Designing hydrogels for controlled drug delivery. Nat Rev Mater. 2016; 1(12): 16071. http:\/\/dx.doi.org\/10.1038\/natrevmats.2016.71 PMID: 29657852","journal-title":"Nat Rev Mater"},{"key":"ref=47","first-page":"22","volume":"3(110","author":"Srikanth,K.","year":"2012","unstructured":"Srikanth,K.; Rama Mohan,Gupta,V.; Manvi,SR. Particulate carrier systems: a review. Int Res J Pharm. 2012; 3(110: 22-6","journal-title":"Int Res J Pharm"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1182\/blood-2002-12-3793","volume":"102(1)","author":"Xia,YP.","year":"2003","unstructured":"Xia,YP.; Li,B.; Hylton,D.; Detmar,M.; Yancopoulos,GD.; Rudge,JS. Transgenic delivery of VEGF to mouse skin leads to an inflamma-tory condition resembling human psoriasis. Blood. 2003; 102(1): 161-8. http:\/\/dx.doi.org\/10.1182\/blood-2002-12-3793 PMID: 12649136","journal-title":"Blood"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5138\/ijdd.2010.0975.0215.02025","volume":"2(2)","author":"Behera,J.","year":"2010","unstructured":"Behera,J.; Keservani,RK.; Yadav,A.; Tripathi,M.; Chadoker,A. Met-hoxsalen loaded chitosan coated microemulsion for effective treat-ment of psoriasis. Int J Drug Deliv. 2010; 2(2): 159-67. http:\/\/dx.doi.org\/10.5138\/ijdd.2010.0975.0215.02025","journal-title":"Int J Drug Deliv"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0168-3659(00) 00309-6","volume":"69(1)","author":"Baroli,B.","year":"2000","unstructured":"Baroli,B.; L\u00f3pez-Quintela,MA.; Delgado-Charro,MB.; Fadda,AM.; Blanco-M\u00e9ndez,J. Microemulsions for topical delivery of 8-methoxsalen. J Control Release. 2000; 69(1): 209-18. http:\/\/dx.doi.org\/10.1016\/S0168-3659(00) 00309-6 PMID: 11018558","journal-title":"J Control Release"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3109\/1061186X.2015.1058804","volume":"24(2)","author":"Amarji,B.","year":"2016","unstructured":"Amarji,B.; Garg,NK.; Singh,B.; Katare,OP. Microemulsions media-ted effective delivery of methotrexate hydrogel: More than a tour de force in psoriasis therapeutics. J Drug Target. 2016; 24(2): 147-60. http:\/\/dx.doi.org\/10.3109\/1061186X.2015.1058804 PMID: 26204326","journal-title":"J Drug Target"},{"key":"ref=52","first-page":"104","volume":"6(1)","author":"Halnor,VV.","year":"2018","unstructured":"Halnor,VV.; Pande,VV.; Borawake,DD.; Nagare,HS. Nanoemulsion: A novel platform for drug delivery system. J Mat Sci Nanotechol. 2018; 6(1): 104","journal-title":"J Mat Sci Nanotechol"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.nano.2018.11.017","volume":"17","author":"Sieber,S.","year":"2019","unstructured":"Sieber S, Grossen P, Uhi P.;et al. Zebrafish as a predictive scree-ning model to assess macrophage clearance of liposomes in vivo. Nanomedicine. 2019; 17: 82-93","journal-title":"Nanomedicine"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/08982104.2019.1593449","volume":"30(1)","author":"Walunj,M.","year":"2019","unstructured":"Walunj,M.; Doppalapudi,S.; Bulbake,U.; Khan,W. Preparation, cha-racterization, and in vivo evaluation of cyclosporine cationic lipo-somes for the treatment of psoriasis. J Liposome Res. 2019; 30(1): 68-79. http:\/\/dx.doi.org\/10.1080\/08982104.2019.1593449 PMID: 30897993","journal-title":"J Liposome Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0378-5173(01) 00810-9","volume":"228(1-2)","author":"Agarwal,R.","year":"2001","unstructured":"Agarwal,R.; Katare,OP.; Vyas,SP. Preparation and in vitro evalua-tion of liposomal\/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm. 2001; 228(1-2): 43-52. http:\/\/dx.doi.org\/10.1016\/S0378-5173(01) 00810-9 PMID: 11576767","journal-title":"Int J Pharm"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.3109\/10717544.2015.1110845","volume":"23(4)","author":"Wadhwa,S.","year":"2016","unstructured":"Wadhwa,S.; Singh,B.; Sharma,G.; Raza,K.; Katare,OP. Liposomal fusidic acid as a potential delivery system: A new paradigm in the treatment of chronic plaque psoriasis. Drug Deliv. 2016; 23(4): 1204-13. http:\/\/dx.doi.org\/10.3109\/10717544.2015.1110845 PMID: 26592918","journal-title":"Drug Deliv"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ijpharm.2012.01.045","volume":"427(2)","author":"Srisuk,P.","year":"2012","unstructured":"Srisuk,P.; Thongnopnua,P.; Raktanonchai,U.; Kanokpanont,S. Physi-co-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal deli-very targeting psoriasis treatment. Int J Pharm. 2012; 427(2): 426-34. http:\/\/dx.doi.org\/10.1016\/j.ijpharm.2012.01.045 PMID: 22310459","journal-title":"Int J Pharm"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jconrel.2011.12.016","volume":"160(2)","author":"Avramoff,A.","year":"2012","unstructured":"Avramoff,A.; Khan,W.; Ezra,A.; Elgart,A.; Hoffman,A.; Domb,AJ. Cyclosporin pro-dispersion liposphere formulation. J Control Re-lease. 2012; 160(2): 401-6. http:\/\/dx.doi.org\/10.1016\/j.jconrel.2011.12.016 PMID: 22227025","journal-title":"J Control Re-lease"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.2147\/IJN.S105016","volume":"11","author":"Abdulbaqi,IM.","year":"2016","unstructured":"Abdulbaqi,IM.; Darwis,Y.; Khan,NA.; Assi,RA.; Khan,AA. Ethoso-mal nanocarriers: The impact of constituents and formulation tech-niques on ethosomal properties, in vivo studies, and clinical trials. Int J Nanomedicine. 2016; 11: 2279-304. http:\/\/dx.doi.org\/10.2147\/IJN.S105016 PMID: 27307730","journal-title":"Int J Nanomedicine"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3109\/10837450.2015.1026605","volume":"21(5)","author":"Avasatthi,V.","year":"2016","unstructured":"Avasatthi,V.; Pawar,H.; Dora,CP.; Bansod,P.; Gill,MS.; Suresh,S. A novel nanogel formulation of methotrexate for topical treatment of psoriasis: optimization, in vitro and in vivo evaluation. Pharm Dev Technol. 2016; 21(5): 554-62. PMID: 26024238","journal-title":"Pharm Dev Technol"},{"key":"ref=61","author":"Korade,S.","unstructured":"Korade,S.; Deshmukh,MT.; Shete,RV. Formulation and evaluation of ethosomal gel containing clobetasol J Eur Pharm Med Res. 2016; 3: 664-72.","journal-title":"2016; 3: 664-72"},{"key":"ref=62","first-page":"1","volume":"201(10)","author":"Garg A","year":"2016","unstructured":"Garg A. Herbal Nanotherapeutics: A noval approach for herbal drug delivery system. J med Pharm Allied Sci. 2016; 201(10): 1","journal-title":"Jmed Pharm Allied Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.freeradbiomed.2013.05.041","volume":"65","author":"Jain,S.","year":"2013","unstructured":"Jain,S.; Jain,AK.; Pohekar,M.; Thanki,K. Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: implications for drug-induced cardiotoxicity and nephrotoxicity. Free Radic Biol Med. 2013; 65: 117-30. http:\/\/dx.doi.org\/10.1016\/j.freeradbiomed.2013.05.041 PMID: 23792276","journal-title":"Free Radic Biol Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.1021\/jf300609p","volume":"60(21)","author":"Yu,H.","year":"2012","unstructured":"Yu,H.; Huang,Q. Improving the oral bioavailability of curcumin using novel organogel-based nanoemulsions. J Agric Food Chem. 2012; 60(21): 5373-9. http:\/\/dx.doi.org\/10.1021\/jf300609p PMID: 22506728","journal-title":"J Agric Food Chem"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1046\/j.1365-3156.1996.d01-91.x","volume":"1(4)","author":"Syed,TA.","year":"1996","unstructured":"Syed,TA.; Ahmad,SA.; Holt,AH.; Ahmad,SA.; Ahmad,SH.; Afzal,M. Management of psoriasis with Aloe vera extract in a hydrophilic cream: A placebo-controlled, double-blind study. Trop Med Int Health. 1996; 1(4): 505-9. http:\/\/dx.doi.org\/10.1046\/j.1365-3156.1996.d01-91.x PMID: 8765459","journal-title":"Trop Med Int Health"},{"key":"ref=66","author":"Horvath F","unstructured":"Horvath F. Therapeutical compositions against psoriasis. US Patent 5165932,1992","journal-title":"US Patent 5165932,1992"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s11745-997-0151-8","volume":"32(11)","author":"Joe,B.","year":"1997","unstructured":"Joe,B.; Lokesh,BR. Effect of curcumin and capsaicin on arachidonic acid metabolism and lysosomal enzyme secretion by rat peritoneal macrophages. Lipids. 1997; 32(11): 1173-80. http:\/\/dx.doi.org\/10.1007\/s11745-997-0151-8 PMID: 9397403","journal-title":"Lipids"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0308-8146(92) 90153-S","volume":"45","author":"Al,Jassir,MS","year":"1992","unstructured":"Al Jassir MS. Chemical composition and microflora of black cumin (Nigella sativa L.) seeds growing in Saudi Arabia. Food Chem. 1992; 45: 239-42. http:\/\/dx.doi.org\/10.1016\/0308-8146(92) 90153-S","journal-title":"Food Chem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.3390\/molecules16053908","volume":"16(5)","author":"Saelee,C.","year":"2011","unstructured":"Saelee,C.; Thongrakard,V.; Tencomnao,T. Effects of Thai medicinal herb extracts with anti-psoriatic activity on the expression on NF-?B signaling biomarkers in HaCaT keratinocytes. Molecules. 2011; 16(5): 3908-32. http:\/\/dx.doi.org\/10.3390\/molecules16053908 PMID: 21555979","journal-title":"Molecules"},{"key":"ref=70","first-page":"176","volume":"1","author":"Shrivastava,S.","year":"2009","unstructured":"Shrivastava,S.; Sindhu,KR.; Kumar,S.; Kumar,S.; Kumar,P. Antipso-riatic and phytochemical evaluation of Thespesiapopulnea bark ex-tracts. Int J Pharma Sci. 2009; 1: 176-85","journal-title":"Int J Pharma Sci"},{"key":"ref=71","author":"Aghmiuni,AI.","unstructured":"Aghmiuni,AI.; Khiavi,AA. Medicinal plants to calm and treat pso-riasis disease. Aromatic and medicinal plants-back to nature, Inte-chOpen: London 2017. http:\/\/dx.doi.org\/10.5772\/67062."},{"key":"ref=72","author":"Cellzome Ltd","unstructured":"Cellzome Ltd. Heterocyclyl pyrimidine analogs as Tyk2 inhi-bitors. US 9296725","journal-title":"US 9296725"},{"key":"ref=73","author":"Roche AG","unstructured":"Roche AG. Thiazolopyridine compounds, compositions and their use as Tyk2 kinase inhibitors. WO Patent 2015091584,2015","journal-title":"WO Patent 2015091584,2015"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ejps.2013.09.023","volume":"51(151)","author":"Puglia,C.","year":"2014","unstructured":"Puglia C, Damiani E, Offerta A.;et al. Evaluation of Nanostructu-red Lipid Carriers (NLC) and nanoemulsions as carriers for UV-filters: characterization, in vitro penetration and photostability stu-dies. Eur J Pharm Sci. 2014; 51(151): 211-7. http:\/\/dx.doi.org\/10.1016\/j.ejps.2013.09.023 PMID: 24157543","journal-title":"Eur J Pharm Sci"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"768","DOI":"10.4103\/0250-474X.49119","volume":"70(6)","author":"Gupta,V.","year":"2008","unstructured":"Gupta,V.; Barupal,AK.; Ramteke,S. Formulation development and in vitro characterization of proliposomes for topical delivery of aceclofenac. Indian J Pharm Sci. 2008; 70(6): 768-75. http:\/\/dx.doi.org\/10.4103\/0250-474X.49119 PMID: 21369438","journal-title":"Indian J Pharm Sci"},{"key":"ref=76","author":"Takeda Pharmaceutical Company Ltd","unstructured":"Takeda Pharmaceutical Company Ltd. Heterocyclic com-pound. WO2015016206., (*excellent Tyk2 inhibitory effect)","journal-title":"WO2015016206, (*excellent Tyk2 inhibitory effect)"},{"key":"ref=77","author":"Lakshimi N","unstructured":"Lakshimi N. Tyk2 inhibitors and uses thereof. WO Patent 2015131080,2015","journal-title":"WO Patent 2015131080,2015"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa030409","volume":"349(21)","author":"Leonardi,CL.","year":"2003","unstructured":"Leonardi CL, Powers JL, Matheson RT.;et al. Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003; 349(21): 2014-22. http:\/\/dx.doi.org\/10.1056\/NEJMoa030409 PMID: 14627786","journal-title":"Etanercept as monotherapy in patients with psoriasis.N Engl J Med"},{"key":"ref=79","author":"Shaw,MH.","unstructured":"Shaw MH, Boyartchuk V, Wong S.;et al. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q\/J mice to infection and autoimmunity. Proc Natl Acad Sci USA 2003; 100(20): 11594-9. http:\/\/dx.doi.org\/10.1073\/pnas.1930781100 PMID: 14500783","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=80","unstructured":"Study of Safety and Efficacy of Topical GSK2981278 \u2013 Cli-nical Trials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02548052 [Accessed 5 April 2016]"},{"key":"ref=81","unstructured":"Research Programme: Autoimmune Disorder Therapies 2010 [Ac-cessed 5 April 2016]"},{"key":"ref=82","unstructured":"Arrien Pharmaceuticals \u2013 Adis Insight [Accessed 5 April 2016]"},{"key":"ref=83","author":"Vitae,Pharma.","unstructured":"Vitae Pharma \u2013 Pipeline. Available from: http:\/\/vitaepharma.com\/ pipeline\/ [Last accessed 10 May 2016]"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/0190-9622(91) 70309-P","volume":"25(6 Pt 1)","author":"Korting,HC.","year":"1991","unstructured":"Korting,HC.; Blecher,P.; Sch\u00e4fer-Korting,M.; Wendel,A. Topical liposome drugs to come: what the patent literature tells us. A re-view. J Am Acad Dermatol. 1991; 25(6 Pt 1): 1068-71. http:\/\/dx.doi.org\/10.1016\/0190-9622(91) 70309-P PMID: 1810984","journal-title":"Are-view.J Am Acad Dermatol"},{"key":"ref=85","author":"Battaglia,L.","unstructured":"Battaglia,L.; Ugazio,E. Lipid Nano-and microparticles: An over-view of patent-related research. J Nanomater 2019. http:\/\/dx.doi.org\/10.1155\/2019\/2834941.","journal-title":"J Nanomater"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1112168","volume":"367(7)","author":"Sandborn,WJ.","year":"2012","unstructured":"Sandborn WJ, Ghosh S, Panes J.;et al. Study A3921063 Investiga-tors. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012; 367(7): 616-24. http:\/\/dx.doi.org\/10.1056\/NEJMoa1112168 PMID: 22894574","journal-title":"N Engl J Med"},{"key":"ref=87","author":"Concert pharmaceuticals Inc","unstructured":"Concert pharmaceuticals Inc. Deuterated derivatives of ruxo-litinib WO Patent 20131887831,2013"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/13543776.2016.1192129","volume":"26(7)","author":"Chiricozzi,A.","year":"2016","unstructured":"Chiricozzi A, Saraceno R, Novelli L.;et al. Small molecules and antibodies for the treatment of psoriasis: A patent review (2010-2015) . Expert Opin Ther Pat. 2016; 26(7): 757-66. http:\/\/dx.doi.org\/10.1080\/13543776.2016.1192129 PMID: 27266423","journal-title":"Expert Opin Ther Pat"},{"key":"ref=89","author":"Schafer,PH.","unstructured":"Schafer,PH.; Gandhi,A.; Capone,L. inventors; Celgene C. Methods and compositions using PDE4 inhibitors for the treatment and ma-nagement of autoimmune and inflammatory diseases. US patent US Patent 9272035,2016.","journal-title":"USpatent US Patent 9272035,2016"},{"key":"ref=90","first-page":"227","volume":"2(4)","author":"Kakar,R.","year":"2010","unstructured":"Kakar,R.; Rao,R.; Goswami,A.; Nanda,S.; Saroha,K. Proniosomes: An emerging vesicular system in drug delivery and cosmetics. Der Pharmacia Lettre. 2010; 2(4): 227-39","journal-title":"Der Pharmacia Lettre"},{"key":"ref=91","author":"Wagner,A. .","unstructured":"Wagner,A.; Vorauer-Uhl,K. Liposome technology for industrial purposes. J Drug Deliv. 2011; 2011","journal-title":"J Drug Deliv"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.colsurfb.2014.05.015","volume":"121(148)","author":"Carrer,DC.","year":"2014","unstructured":"Carrer,DC.; Higa,LH.; Tesoriero,MV.; Morilla,MJ.; Roncaglia,DI.; Romero,EL. Structural features of ultradeformable archaeosomes for topical delivery of ovalbumin. Colloids Surf B Biointerfaces. 2014; 121(148): 281-9. http:\/\/dx.doi.org\/10.1016\/j.colsurfb.2014.05.015 PMID: 24974012","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1021\/bm900248n","volume":"10(6)","author":"Kulkarni,M.","year":"2009","unstructured":"Kulkarni,M.; Breen,A.; Greiser,U.; O\u2019Brien,T.; Pandit,A. Fibrin-lipoplex system for controlled topical delivery of multiple genes. Biomacromolecules. 2009; 10(6): 1650-4. http:\/\/dx.doi.org\/10.1021\/bm900248n PMID: 19385658","journal-title":"Biomacromolecules"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/aps.2010.98","volume":"31(8)","author":"Han,S.","year":"2010","unstructured":"Han S, Shen JQ, Gan Y.;et al. Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability. Acta Pharmacol Sin. 2010; 31(8): 990-8. http:\/\/dx.doi.org\/10.1038\/aps.2010.98 PMID: 20686524","journal-title":"Acta Pharmacol Sin"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"680580.","DOI":"10.1155\/2013\/680580","volume":"2013","author":"Mittal,R.","year":"2013","unstructured":"Mittal,R.; Sharma,A.; Arora,S. Ufasomes mediated cutaneous deli-very of dexamethasone: Formulation and evaluation of anti-inflammatory activity by carrageenininduced rat paw edema model. J Pharm. 2013; 2013: 680580. http:\/\/dx.doi.org\/10.1155\/2013\/680580 PMID: 26555990","journal-title":"J Pharm"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1002\/jps.22104","volume":"99(8)","author":"Manosroi,J.","year":"2010","unstructured":"Manosroi,J.; Khositsuntiwong,N.; Manosroi,W.; G\u00f6tz,F.; Werner,RG.; Manosroi,A. Enhancement of transdermal absorption, gene expres-sion and stability of tyrosinase plasmid (pMEL34)-loaded elastic cationic niosomes: Potential application in vitiligo treatment. J Pharm Sci. 2010; 99(8): 3533-41. http:\/\/dx.doi.org\/10.1002\/jps.22104 PMID: 20213835","journal-title":"J Pharm Sci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.clindermatol.2007.10.025","volume":"26(5)","author":"Bos,JD.","year":"2008","unstructured":"Bos,JD.; Spuls,PI. Topical treatments in psoriasis: today and tomo-rrow. Clin Dermatol. 2008; 26(5): 432-7. http:\/\/dx.doi.org\/10.1016\/j.clindermatol.2007.10.025 PMID: 18755361","journal-title":"Clin Dermatol"}],"container-title":["Recent Patents on Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/179018","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/179018\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/179018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T06:41:29Z","timestamp":1695710489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/179018\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,9,16]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1872210514666200204124130","relation":{},"ISSN":["1872-2105"],"issn-type":[{"value":"1872-2105","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,16]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}